

ANNOUNCEMENT

OF THE MANAGEMENT BOARD OF GENOMTEC S.A. WITH ITS REGISTERED OFFICE IN WROCLAW

ON THE CONVENING OF THE EXTRAORDINARY GENERAL MEETING OF THE COMPANY

The Management Board of Genomtec S.A., with its registered office in Wrocław, at ul. Bierutowska 57-59, 51-317 Wrocław, entered into the Register of Entrepreneurs of the National Court Register kept by the District Court for Wrocław – Fabryczna in Wrocław, VI Commercial Division of the National Court Register, under KRS number: 0000662554, with NIP: 8992809452 and REGON: 365935587, with share capital of PLN 1,332,457.00 – fully paid up (the “**Company**”), acting pursuant to Article 399 § 1 and Article 398 of the Act of September 15, 2000 – the Commercial Companies Code (“**CCC**”) and § 12 section 3 of the Company’s Articles of Association, **hereby convenes the Extraordinary General Meeting of the Company for March 12, 2025, at 12:00 PM.**

The Extraordinary General Meeting of the Company will be held at the Company’s premises in Wrocław (51-317), at ul. Bierutowska 57-59.

Detailed agenda of the Extraordinary General Meeting includes:

1. Opening of the Extraordinary General Meeting.
2. Election of the Chairperson of the Extraordinary General Meeting.
3. Confirmation of the proper convening of the Extraordinary General Meeting and its ability to adopt resolutions.
4. Adoption of the agenda.
5. Adoption of a resolution on increasing the Company’s share capital by issuing new series P bearer ordinary shares, excluding in full the pre-emptive rights of existing shareholders, amending the Company’s Articles of Association, and applying for the admission and introduction of series P shares to trading on the regulated market.
6. Closing of the Extraordinary General Meeting.

At the same time, in accordance with Article 402² of the Commercial Companies Code (CCC), the Management Board of the Company provides the following information:

I. Right to participate in the Extraordinary General Meeting and registration date

Pursuant to Article 406¹ § 1 of the CCC: *“The right to participate in the general meeting of a public company is granted only to persons who are shareholders of the company sixteen days before the date of the general meeting (the registration date for participation in the general meeting).”*

The Management Board of the Company informs that, in accordance with Article 406¹ § 1 of the CCC, the registration date for participation in the Extraordinary General Meeting falls on **February 24, 2025**.

Only persons who are Shareholders of the Company on **February 24, 2025**, are entitled to participate in the Extraordinary General Meeting.

Each Shareholder intending to participate in the Extraordinary General Meeting should request the entity maintaining their securities account to issue a nominal certificate of entitlement to participate in the General Meeting. This request must be submitted to the entity maintaining the securities account no earlier than after the announcement of the convening of the Extraordinary General Meeting and no later than on the first business day after the registration date, i.e., by **February 25, 2025**.

The Company prepares the list of shareholders entitled to participate in the General Meeting (the “**Shareholder List**”) based on the register provided by the National Depository for Securities S.A. (Krajowy Depozyt Papierów Wartościowych S.A.), which compiles the list based on the nominal certificates issued by the entities maintaining securities accounts.

The Shareholder List, signed by the Management Board, will be available for review at the Company's Management Board Secretariat in Wrocław, at ul. Bierutowska 57-59, for three business days preceding the date of the Extraordinary General Meeting (from **March 7, 2025**, to **March 11, 2025**), from 9:00 AM to 5:00 PM.

A Shareholder may review the Shareholder List at the above-mentioned location and request a copy of the Shareholder List at their expense. A Shareholder may also request that the Shareholder List be sent free of charge to an electronic address designated for this purpose or an email address. Such a request must be made electronically and sent to: investors@genomtec.com or submitted in writing at the Company's headquarters in the Management Board Secretariat (ul. Bierutowska 57-59, 51-317 Wrocław).

Legal entity shareholders' proxies are requested to report to the shareholder registration point at least 30 minutes before the start of the General Meeting.

II. Description of procedures for participation in the Extraordinary General Meeting and exercising voting rights

1. Shareholders' right to request the inclusion of specific matters in the agenda

The Management Board of the Company informs that a Shareholder or Shareholders representing at least one-twentieth of the Company's share capital may request the inclusion of specific matters in the agenda of the Extraordinary General Meeting. Such a request should be submitted to the Management Board of the Company no later than twenty-one days before the scheduled date of the Extraordinary General Meeting, i.e., by February 19, 2025. The Shareholder's request should include a justification or a draft resolution concerning the proposed agenda item. The request may be submitted in writing at the Management Board Secretariat of the Company: Genomtec S.A., ul. Bierutowska 57-59, 51-317 Wrocław, or electronically to the following email address: investors@genomtec.com.

The request must be accompanied by:

A deposit certificate or certificate of entitlement to participate in the Extraordinary General Meeting issued by the entity maintaining the securities account where the Shareholder's shares in the Company are registered. This certificate must confirm that, as of the date of submission, the Shareholder holds shares in the Company and represents (individually or jointly with other applicants) at least one-twentieth of the Company's share capital.

Copies of documents confirming the identity of the Shareholder or the persons acting on their behalf.

The timely submission of the request shall be determined by: (i) For written requests – the date of delivery to the Company's address, and (ii) For electronic requests – the date the request is recorded in the Company's email system (the date of receipt by the Company's incoming mail server).

The Management Board of the Company will immediately, but no later than eighteen days before the scheduled date of the Extraordinary General Meeting (i.e., by **February 22, 2025**), announce changes to the agenda introduced at the request of Shareholders.

Any such announcement will be published on the Company's website: <https://genomtec.com/akcje/#walne-zgromadzenie> and in accordance with the procedures for disclosing current information as specified in the Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies.

All risks associated with the use of electronic communication devices by the Shareholder remain solely with the Shareholder.

2. Shareholder's right to submit draft resolutions regarding matters included in the agenda of the General Meeting or matters to be added to the agenda before the date of the General Meeting

The Management Board informs that a Shareholder or Shareholders of the Company representing at least one-twentieth of the Company's share capital may, before the date of the Extraordinary General

Meeting, submit to the Company, in writing at the Management Board Secretariat of the Company: Genomtec S.A., ul. Bierutowska 57-59, 51-317 Wrocław, or via electronic communication to the email address: investors@genomtec.com, draft resolutions concerning matters included in the agenda of the Extraordinary General Meeting or matters to be added to the agenda.

The submission by the Shareholder(s) must be accompanied by:

A deposit certificate or certificate of entitlement to participate in the Extraordinary General Meeting, issued by the entity maintaining the securities account where the Shareholder's shares in the Company are registered. This certificate must confirm that, as of the submission date, the Shareholder holds shares in the Company and represents (individually or jointly with other applicants) at least one-twentieth of the Company's share capital.

Copies of documents confirming the identity of the Shareholder or the persons acting on their behalf.

The timely submission of the request shall be determined by: (i) For written submissions – the date of delivery to the Company's address, and (ii) For electronic submissions – the date the request is recorded in the Company's email system (the date of receipt by the Company's incoming mail server).

The Company will promptly publish the draft resolutions on its website: <https://genomtec.com/akcje/#walne-zgromadzenie> and in accordance with the procedures for disclosing current information as specified in the Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies.

All risks associated with the use of electronic communication devices by the Shareholder remain solely with the Shareholder.

3. The Shareholder's right to submit draft resolutions regarding matters included in the agenda during the General Meeting.

In accordance with Article 401 § 5 of the Commercial Companies Code (CCC), each Shareholder may submit draft resolutions regarding matters included in the agenda during the Extraordinary General Meeting.

The Management Board of the Company informs that each Shareholder has the right to propose amendments and additions to the draft resolutions included in the agenda of the Extraordinary General Meeting until the Chairperson of the Meeting closes the discussion on the agenda item related to the draft resolution in question.

Proposals, along with a brief justification, should be submitted in writing, separately for each draft resolution, stating the Shareholder's full name (or company name), and handed to the Chairperson of the Meeting. The Chairperson may permit the proposal to be presented orally.

Proposals for amendments and additions of a formal, technical, or linguistic nature may be submitted orally with a brief justification, unless, due to the scope of the proposed changes, the Chairperson of the Meeting decides that the proposal should be submitted in writing.

4. Method of Exercising Voting Rights by a Proxy, Including the Use of Proxy Voting Forms. Method of Notifying the Company About the Appointment of a Proxy Using Electronic Communication

The Management Board informs that each Shareholder of the Company may participate in the Extraordinary General Meeting and exercise their voting rights either personally or through a proxy.

The right to represent a Shareholder that is not a natural person should be confirmed by the appropriate register entry, a chain of powers of attorney, or other corporate documents confirming the authorization to represent the Shareholder when preparing the attendance list.

A proxy exercises all rights of the Shareholder at the General Meeting, unless the content of the power of attorney states otherwise. A proxy may also grant further powers of attorney, if allowed by the original power of attorney.

A proxy may represent more than one Shareholder and vote differently on behalf of each Shareholder. Each Shareholder holding shares in more than one securities account may appoint separate proxies to exercise voting rights from the shares registered in each account.

The power of attorney for participation in the Extraordinary General Meeting and the exercise of voting rights must be granted in writing or electronically. A power of attorney granted in electronic form does not require a qualified electronic signature.

The Shareholder must attach to the power of attorney:

An excerpt from the relevant register that is current as of the date of granting the power of attorney or other corporate documents confirming the Shareholder's authorization to issue the power of attorney.

If the documents referred to in the previous sentence are not in Polish, a certified translation must be provided.

Copies of documents may be submitted if certified as true copies by a notary public, attorney, or legal advisor.

The Company provides a template proxy voting form on its website at:

 <https://genomtec.com/akcje/#walne-zgromadzenie>.

A Shareholder voting through a proxy may use the form available on the website, but using this form is not mandatory—it is an optional right for each Shareholder. The form does not constitute a power of attorney and does not replace the power of attorney required for participation in the Extraordinary General Meeting.

Electronic Notification of a Power of Attorney

According to point 2.3 of the Company's General Meeting Regulations, a Shareholder should notify the Company about granting a power of attorney in electronic form by sending an email to investors@genomtec.com no later than the end of the day preceding the General Meeting.

The Company's website provides a template notification form for granting a power of attorney electronically, which should be filled out by the Shareholder and sent as an attachment to the above email address. The notification must be accompanied by a certificate of entitlement to participate in the Extraordinary General Meeting.

These rules also apply to revoking a power of attorney. A Shareholder who revokes a power of attorney must promptly inform the Management Board by sending an email to investors@genomtec.com. If the power of attorney was granted in writing, the revocation must also be submitted in writing, either in person or by registered mail to the Company's address.

Voting by Proxy Using a Form

If a proxy exercises voting rights using a proxy voting form, the form must be delivered to the Chairperson of the Meeting before the voting on the respective resolution is concluded.

The Management Board informs that the Company is not obligated to verify whether the proxy complies with the voting instructions received from the Shareholder, as specified in Article 412² § 4 of the Commercial Companies Code.

The Company is authorized to take steps to verify the validity of the submitted powers of attorney.

Proxy Appointment for the Extraordinary General Meeting

Members of the Management Board and employees of the Company may act as proxies at the Extraordinary General Meeting. If the proxy is a Management Board member, a Supervisory Board member, a liquidator, or an employee of the Company, the power of attorney may authorize representation only at a single Extraordinary General Meeting.

A proxy in such a case is required to disclose to the Shareholder any circumstances indicating a conflict of interest or the possibility of such a conflict arising. In such situations:

The proxy cannot grant further powers of attorney.

The proxy must vote in accordance with the instructions given by the Shareholder.

The Company may, at its discretion, allow a Shareholder who is a natural person to grant a power of attorney to a designated Company employee for participation in the Extraordinary General Meeting and the exercise of voting rights. A Shareholder interested in this option must notify the Company at least three days before the date of the Extraordinary General Meeting by sending an email to investors@genomtec.com.

All risks related to exercising voting rights through a proxy rest solely with the Shareholder.

5. Possibility and Method of Participating in the Extraordinary General Meeting Using Electronic Means of Communication. Method of Speaking During the Extraordinary General Meeting Using Electronic Means of Communication. Method of Exercising Voting Rights by Correspondence or Using Electronic Means of Communication.

The Company does not provide for the possibility of participating in the Extraordinary General Meeting using electronic means of communication.

The Company does not provide for the possibility of speaking during the Extraordinary General Meeting using electronic means of communication.

The Company's General Meeting Regulations do not allow for the exercise of voting rights by correspondence.

The Company does not provide for the possibility of exercising voting rights using electronic means of communication.

6. The Shareholder's right to ask questions regarding matters included in the agenda of the Extraordinary General Meeting.

During the Extraordinary General Meeting, a Shareholder has the right to ask questions regarding matters included in the agenda of the Extraordinary General Meeting. Pursuant to Article 428 § 1 of the Commercial Companies Code (CCC), the Management Board of the Company is obliged to provide a Shareholder, upon their request, with information regarding the Company, if it is justified for the assessment of matters included in the agenda. The Management Board of the Company may refuse to provide information if its disclosure could cause harm to the Company, a related company, or a subsidiary company or cooperative, particularly by revealing the technical, trade, or organizational secrets of the enterprise. A member of the Management Board may also refuse to provide information if its disclosure could constitute grounds for criminal, civil, or administrative liability.

III. Proposed amendments to the Articles of Association

In connection with item 5 of the proposed agenda of the Extraordinary General Meeting (Adoption of a resolution on increasing the Company's share capital through the issuance of new series P bearer ordinary shares, with the full exclusion of pre-emptive rights of existing shareholders, amendment of the Company's Articles of Association, and application for the admission and introduction of series P shares to trading on the regulated market), § 7 sections 1 and 2 of the Company's Articles of Association, in their current wording:

1. *"The Company's share capital amounts to PLN 1,332,457.00 (one million three hundred thirty-two thousand four hundred fifty-seven zlotys) and is divided into 13,324,570 (thirteen million three hundred twenty-four thousand five hundred seventy) bearer ordinary shares, each with a nominal value of PLN 0.10 (ten groszy).*
2. *The share capital is divided into:*
 - a) *1,000,000 series A bearer ordinary shares,*

- b) 142,860 series B bearer ordinary shares,
- c) 4,000,000 series C bearer ordinary shares,
- d) 583,670 series D bearer ordinary shares,
- e) 85,900 series E bearer ordinary shares,
- f) 76,000 series F bearer ordinary shares,
- g) 710,110 series G bearer ordinary shares,
- h) 830,000 series H bearer ordinary shares,
- i) 730,000 series J bearer ordinary shares,
- j) 1,205,639 series K bearer ordinary shares,
- k) 794,361 series L bearer ordinary shares,
- l) 1,237,000 series M bearer ordinary shares,
- m) 400,000 series N bearer ordinary shares,
- n) 462,346 series I bearer ordinary shares,
- o) 1,066,684 series O bearer ordinary shares."

shall be amended to read as follows:

1. „The Company's share capital shall be no less than PLN 1,332,457.10 (one million three hundred thirty-two thousand four hundred fifty-seven zlotys and ten groszy) and no more than PLN 1,512,457.00 (one million five hundred twelve thousand four hundred fifty-seven zlotys) and shall be divided into no fewer than 13,324,571 (thirteen million three hundred twenty-four thousand five hundred seventy-one) and no more than 15,124,570 (fifteen million one hundred twenty-four thousand five hundred seventy) bearer ordinary shares, each with a nominal value of PLN 0.10 (ten groszy).
2. The share capital is divided into:
 - a) 1,000,000 series A bearer ordinary shares,
 - b) 142,860 series B bearer ordinary shares,
 - c) 4,000,000 series C bearer ordinary shares,
 - d) 583,670 series D bearer ordinary shares,
 - e) 85,900 series E bearer ordinary shares,
 - f) 76,000 series F bearer ordinary shares,
 - g) 710,110 series G bearer ordinary shares,
 - h) 830,000 series H bearer ordinary shares,
 - i) 730,000 series J bearer ordinary shares,
 - j) 1,205,639 series K bearer ordinary shares,
 - k) 794,361 series L bearer ordinary shares,
 - l) 1,237,000 series M bearer ordinary shares,
 - m) 400,000 series N bearer ordinary shares,
 - n) 462,346 series I bearer ordinary shares,
 - o) 1,066,684 series O bearer ordinary shares, and

p) no fewer than 1 and no more than 1,800,000 series P bearer ordinary shares."

IV. Possibility of Obtaining Information Regarding the Extraordinary General Meeting. Indication of the Website Address Where Information Regarding the Extraordinary General Meeting Will Be Made Available.

The full documentation to be presented at the Extraordinary General Meeting, the draft resolutions of the Extraordinary General Meeting, and all other information related to the Extraordinary General Meeting will be published on the Company's website at: <https://genomtec.com/akcje/#walnezgromadzenie> as well as at the Company's registered office (ul. Bierutowska 57-59, 51-317 Wrocław) starting from the date of the announcement of the Extraordinary General Meeting.

A Shareholder has the right to request a copy of the motions concerning matters included in the agenda one week before the General Meeting.